Standout Papers

Inflammation in atherosclerosis 2002 2026 2010 2018 6.3k
  1. Inflammation in atherosclerosis (2002)
    Peter Libby Nature
  2. Inflammation and Atherosclerosis (2002)
    Peter Libby, Paul M. Ridker et al. Circulation
  3. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (2008)
    Paul M. Ridker, Eleanor Danielson et al. New England Journal of Medicine
  4. Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein (2009)
    Paul M. Ridker, Eleanor Danielson et al. Obstetrical & Gynecological Survey
  5. Progress and challenges in translating the biology of atherosclerosis (2011)
    Peter Libby, Paul M. Ridker et al. Nature
  6. Inflammation in Atherosclerosis (2012)
    Peter Libby Arteriosclerosis Thrombosis and Vascular Biology
  7. Diabetes and Atherosclerosis (2002)
    Joshua A. Beckman, Mark A. Creager et al. JAMA
  8. Atherosclerosis (2019)
    Peter Libby, Julie E. Buring et al. Nature Reviews Disease Primers
  9. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions (2007)
    Matthias Nahrendorf, Filip K. Świrski et al. The Journal of Experimental Medicine
  10. The immune response in atherosclerosis: a double-edged sword (2006)
    Göran K. Hansson, Peter Libby Nature reviews. Immunology
  11. Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites (2009)
    Filip K. Świrski, Matthias Nahrendorf et al. Science
  12. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (2011)
    Douglas L. Mann, Douglas P. Zipes et al. Medical Entomology and Zoology
  13. Inflammation in Atherosclerosis (2009)
    Peter Libby, Paul M. Ridker et al. Journal of the American College of Cardiology
  14. The changing landscape of atherosclerosis (2021)
    Peter Libby Nature
  15. Molecular Bases of the Acute Coronary Syndromes (1995)
    Peter Libby Circulation
  16. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis (2006)
    Steven E. Nissen, Stephen J. Nicholls et al. JAMA
  17. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. (1995)
    Raffaele De Caterina, Peter Libby et al. Journal of Clinical Investigation
  18. Pathophysiology of Coronary Artery Disease (2005)
    Peter Libby, Pierre Théroux Circulation
  19. Absence of Monocyte Chemoattractant Protein-1 Reduces Atherosclerosis in Low Density Lipoprotein Receptor–Deficient Mice (1998)
    Long Gu, Yoshikatsu Okada et al. Molecular Cell
  20. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes (2001)
    Peter Libby Circulation
  21. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata (2007)
    Filip K. Świrski, Peter Libby et al. Journal of Clinical Investigation
  22. Inflammation and cardiovascular disease mechanisms (2006)
    Peter Libby American Journal of Clinical Nutrition
  23. Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy (2013)
    Peter Libby New England Journal of Medicine
  24. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells (1989)
    Kurt R. Auger, Leslie A. Serunian et al. Cell
  25. Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis (2002)
    Göran K. Hansson, Peter Libby et al. Circulation Research
  26. Local proliferation dominates lesional macrophage accumulation in atherosclerosis (2013)
    Clinton S. Robbins, Ingo Hilgendorf et al. Nature Medicine
  27. Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure (2004)
    Steven E. Nissen, E. Murat Tuzcu et al. JAMA
  28. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial (2009)
    Paul M. Ridker, Eleanor Danielson et al. The Lancet
  29. Reduction of atherosclerosis in mice by inhibition of CD40 signalling (1998)
    François Mach, Uwe Schönbeck et al. Nature
  30. Obesity, inflammation, and atherosclerosis (2009)
    Viviane Zorzanelli Rocha, Peter Libby Nature Reviews Cardiology
  31. Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction (2007)
    René R. Sevag Packard, Peter Libby Clinical Chemistry
  32. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction (2000)
    Anique Ducharme, Stefan Frantz et al. Journal of Clinical Investigation
  33. Targeting inflammation in atherosclerosis — from experimental insights to the clinic (2021)
    Oliver Soehnlein, Peter Libby Nature Reviews Drug Discovery
  34. Effect of Two Intensive Statin Regimens on Progression of Coronary Disease (2011)
    Stephen J. Nicholls, Christie M. Ballantyne et al. New England Journal of Medicine
  35. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models (2008)
    Christian Weber, Alma Zernecke et al. Nature reviews. Immunology
  36. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) (2011)
    Paul M. Ridker, Tom Thurén et al. American Heart Journal
  37. The CD40/CD154 receptor/ligand dyadRID="†"ID="†" Review (2001)
    Peter Libby et al. Cellular and Molecular Life Sciences
  38. COVID-19 is, in the end, an endothelial disease (2020)
    Peter Libby, Thomas F. Lüscher European Heart Journal
  39. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice (2009)
    Jian Liu, Adeline Divoux et al. Nature Medicine
  40. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40–CD40 ligand signaling in atherosclerosis (1997)
    François Mach, Uwe Schönbeck et al. Proceedings of the National Academy of Sciences
  41. Inflammation and plaque vulnerability (2015)
    Göran K. Hansson, Peter Libby et al. Journal of Internal Medicine
  42. Macrophage Myeloperoxidase Regulation by Granulocyte Macrophage Colony-Stimulating Factor in Human Atherosclerosis and Implications in Acute Coronary Syndromes (2001)
    Seigo Sugiyama, Yoshikatsu Okada et al. American Journal Of Pathology
  43. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. (1994)
    Zorina S. Galis, Galina K. Sukhova et al. Circulation Research
  44. Inflammation in Atherosclerosis: Transition From Theory to Practice (2010)
    Peter Libby, Yoshihisa Okamoto et al. Circulation Journal
  45. Induction and Stabilization of IκBα by Nitric Oxide Mediates Inhibition of NF-κB (1995)
    Haibing Peng, Peter Libby et al. Journal of Biological Chemistry
  46. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. (1998)
    Uwe Schönbeck, François Mach et al. PubMed
  47. Cardiovascular remodelling in coronary artery disease and heart failure (2014)
    Gerd Heusch, Peter Libby et al. The Lancet
  48. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. (1991)
    Peter Libby, Göran K. Hansson PubMed
  49. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial (2012)
    Paul M. Ridker, Aruna D. Pradhan et al. The Lancet
  50. Chronic variable stress activates hematopoietic stem cells (2014)
    Timo Heidt, Hendrik B. Sager et al. Nature Medicine
  51. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. (1993)
    H. Li, Myron I. Cybulsky et al. Arteriosclerosis and Thrombosis A Journal of Vascular Biology
  52. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. (1995)
    Yong‐Jian Geng, Peter Libby PubMed
  53. Atherosclerosis and inflammation: overview and updates (2018)
    Glaucylara Reis Geovanini, Peter Libby Clinical Science
  54. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism (2009)
    Robert J. Glynn, Eleanor Danielson et al. New England Journal of Medicine
  55. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. (1998)
    Galina K. Sukhova, Guo‐Ping Shi et al. Journal of Clinical Investigation
  56. Generation of Biologically Active IL-1β by Matrix Metalloproteinases: A Novel Caspase-1-Independent Pathway of IL-1β Processing (1998)
    Uwe Schönbeck, François Mach et al. The Journal of Immunology
  57. Evidence for Increased Collagenolysis by Interstitial Collagenases-1 and -3 in Vulnerable Human Atheromatous Plaques (1999)
    Galina K. Sukhova, Uwe Schönbeck et al. Circulation
  58. Inflammation and Cellular Immune Responses in Abdominal Aortic Aneurysms (2006)
    Koïchi Shimizu, Richard N. Mitchell et al. Arteriosclerosis Thrombosis and Vascular Biology
  59. Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans (2013)
    Peter Libby, Andrew H. Lichtman et al. Immunity
  60. Interleukins in cancer: from biology to therapy (2021)
    Daria Briukhovetska, Janina Dörr et al. Nature reviews. Cancer
  61. Interleukin-1 Beta as a Target for Atherosclerosis Therapy (2017)
    Peter Libby Journal of the American College of Cardiology
  62. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure (2019)
    Brendan M. Everett, Jan H. Cornel et al. Circulation
  63. Ly-6C high Monocytes Depend on Nr4a1 to Balance Both Inflammatory and Reparative Phases in the Infarcted Myocardium (2014)
    Ingo Hilgendorf, Louisa M.S. Gerhardt et al. Circulation Research
  64. The Aging Cardiovascular System (2017)
    Francesco Paneni, Candela Díaz-Cañestro et al. Journal of the American College of Cardiology
  65. IRF3 and type I interferons fuel a fatal response to myocardial infarction (2017)
    Kevin R. King, Aaron D. Aguirre et al. Nature Medicine
  66. Inflammation, Immunity, and Infection in Atherothrombosis (2018)
    Peter Libby, Joseph Loscalzo et al. Journal of the American College of Cardiology
  67. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial (2021)
    Paul M. Ridker, Matt Devalaraja et al. The Lancet
  68. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) (2018)
    Paul M. Ridker, Peter Libby et al. European Heart Journal
  69. Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure (2016)
    Hendrik B. Sager, Maarten Hulsmans et al. Circulation Research
  70. Acute Coronary Syndromes (2017)
    Filippo Crea, Peter Libby Circulation
  71. Reassessing the Mechanisms of Acute Coronary Syndromes (2019)
    Peter Libby, Gerard Pasterkamp et al. Circulation Research
  72. Genesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques (2016)
    Joshua D. Hutcheson, Claudia Goettsch et al. Nature Materials
  73. Inflammation during the life cycle of the atherosclerotic plaque (2021)
    Peter Libby Cardiovascular Research
  74. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid (2020)
    R. Preston Mason, Peter Libby et al. Arteriosclerosis Thrombosis and Vascular Biology
  75. Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis (2019)
    Alexander G. Bick, James P. Pirruccello et al. Circulation
  76. Neutrophil Extracellular Traps Participate in Cardiovascular Diseases (2020)
    Yvonne Döring, Peter Libby et al. Circulation Research
  77. Ferritinophagy and ferroptosis in the management of metabolic diseases (2021)
    Amir Ajoolabady, Peter Libby et al. Trends in Endocrinology and Metabolism
  78. Inflammation, Aging, and Cardiovascular Disease (2022)
    Luca Liberale, Lina Badimón et al. Journal of the American College of Cardiology
  79. Neutrophil extracellular traps: from physiology to pathology (2021)
    Andrés Hidalgo, Peter Libby et al. Cardiovascular Research
  80. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab (2022)
    E. C. Svensson, Aviv Madar et al. JAMA Cardiology

Immediate Impact

4 by Nobel laureates 44 from Science/Nature 122 standout
Sub-graph 1 of 19

Citing Papers

The integrative biology of type 2 diabetes
2019 StandoutNature
cGAS in action: Expanding roles in immunity and inflammation
2019 StandoutScience
1 intermediate paper

Works of Peter Libby being referenced

Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
2018
IRF3 and type I interferons fuel a fatal response to myocardial infarction
2017 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Peter Libby 48104 38575 34775 35600 757 144.2k
Paul M. Ridker 20587 40769 37641 17983 811 127.8k
Russell Ross 17410 16428 13058 24997 241 78.4k
Charles A. Dinarello 46442 10618 5141 36261 864 106.0k
Joseph L. Witztum 26213 21273 10105 18095 455 70.4k
Yūji Matsuzawa 8225 14563 16320 16433 694 78.6k
Nader Rifai 8913 20465 20862 9021 450 75.0k
Michael Karin 59606 13163 4246 112099 646 209.7k
Scott M. Grundy 5116 50319 38940 18645 582 156.3k
Christian Weber 22205 9620 7817 22208 1.1k 67.8k
Valentı́n Fuster 8297 33107 52301 9561 1.3k 98.0k

All Works

Loading papers...

Rankless by CCL
2026